Adult Vaccines Market Report 2026

The adult vaccines market size has grown strongly in recent years. It will grow from $24.21 billion in 2025 to $26.34 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rising prevalence of infectious diseases, government immunization initiatives, development of novel vaccines, growing geriatric population, increasing healthcare infrastructure.

The adult vaccines market size is expected to see strong growth in the next few years. It will grow to $37.51 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to advancement in mRNA and recombinant vaccine technologies, increasing investment in adult immunization programs, expansion of cold chain logistics, rising awareness of vaccine-preventable diseases, collaborations between pharma and biotech companies. Major trends in the forecast period include increasing adult vaccination awareness, expansion of immunization programs, development of combination vaccines, growth in chronic disease management vaccines, rising demand for travel and occupational vaccines.

The increase in healthcare expenditure supported the growth of the adult vaccine market. Healthcare expenditure refers to the total spending on healthcare services provided to a population. Increased healthcare spending often leads to greater investment in medical research and development. By directing resources toward vaccination programs and expanding access to vaccines, healthcare systems can reduce the prevalence of preventable diseases and improve overall population health. In addition, adult vaccination can result in significant cost savings by lowering healthcare utilization and minimizing the need for expensive treatments. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based health organization, Canada’s total health expenditure in 2023 was projected to reach $344 billion, reflecting an increase of over $9 billion compared to 2022. As a result, the rise in healthcare expenditure positively contributed to the growth of the adult vaccine market.

Major companies are operating in the adult vaccines market and are concentrating on advancing technologies such as mRNA-based vaccines to facilitate rapid and targeted immune response generation in response to the increasing demand for adult immunization against respiratory diseases. An mRNA vaccine employs messenger RNA encapsulated in lipid nanoparticles to instruct human cells to produce specific viral proteins, thereby inducing an immune response without the use of live or attenuated viruses. For instance, in May 2024, Moderna, a US-based biotechnology company, obtained FDA approval for mRESVI, an mRNA-based respiratory syncytial virus (RSV) vaccine for adults aged 60 years and older. The vaccine encodes the prefusion F glycoprotein of RSV and is delivered as a single-dose, pre-filled syringe, promoting neutralizing antibody production, improving safety and efficacy compared to traditional inactivated or live-attenuated vaccines, and expanding adult immunization options.

In December 2023, AstraZeneca, a UK-based developer of respiratory and immune-therapeutic vaccines, acquired Icosavax for up to US$ 1.1 billion. Through this acquisition, AstraZeneca aims to enhance its adult vaccine portfolio by integrating Icosavax’s virus-like particle (VLP) vaccine platform and advancing its lead candidate, IVX-A12, a combined RSV and hMPV vaccine intended for older adults. Icosavax, Inc. is a US-based biopharmaceutical company specializing in the development of virus-like particle (VLP) vaccines for respiratory infections in adults.

Major companies operating in the adult vaccines market are GlaxoSmithKline PLC, Merck & Co, Sanofi Pasteur, Pfizer Inc, Commonwealth Serum Laboratories Limited, Johnson & Johnson, Serum Institute of India, AstraZeneca PLC, Novartis AG, Protein Sciences Corporation, Emergent BioSolutions Inc., Bavarian Nordic A/S, Dynavax Technologies Corporation, Novavax Inc, Medimmune LLC, BioNTech SE, Moderna, Inovio Pharmaceuticals, Sinovac, Valneva Se, Biological E Limited, Panacea Biotec, Shenzhen Kangtai Biological Products, Beijing Tiantan Biological Products, Hualan Biological Engineering, Chengdu Institute of Biological Products, Bharat Biotech International Limited, Takeda Pharmaceutical Company Limited.

North America was the largest region in the adult vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the adult vaccines market during the forecast period. The regions covered in the adult vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adult vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the adult vaccines market by increasing import costs of raw materials, biopharmaceutical equipment, and specialized reagents, thereby affecting vaccine production and distribution. Segments like recombinant vaccines and multivalent vaccines are most affected, particularly in regions dependent on imported inputs such as Europe and Asia-Pacific. While tariffs have raised costs and slowed market expansion in some regions, they have also encouraged local manufacturing and investment in domestic production capabilities, creating opportunities for regional vaccine self-sufficiency.

The adult vaccines market research report is one of a series of new reports that provides adult vaccines market statistics, including adult vaccines industry global market size, regional shares, competitors with a adult vaccines market share, detailed adult vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the adult vaccines industry. This adult vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adult vaccines are immunizations administered to induce an immune response against disease-causing pathogens in adults. These vaccines are used for both disease prevention and management. Vaccination helps lessen the severity of illness among individuals at higher risk, such as those with chronic medical conditions or weakened immune systems.

The main types of adult vaccines include monovalent and multivalent vaccines. A monovalent vaccine contains the mRNA component of a single virus and is intended to generate an immune response against one specific antigen. The technologies employed include live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines. These vaccines are used across a range of indications, including influenza, dPT, human papillomavirus, zoster, pneumococcal disease, and hepatitis, and are administered by healthcare organizations and hospitals.

The adult vaccines market consists of sales of mRNA vaccines and viral vector vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.